Kardigan, Inc. has announced a significant milestone in its clinical research efforts. The company reported that it has completed enrollment in its Phase 2b KATALYST-AV trial of ataciguat, a treatment aimed at patients with aortic stenosis. This event is crucial as it marks a step forward in the development of therapies for heart conditions, which are a major health concern worldwide.
The KATALYST-AV trial will assess the primary endpoint of aortic valve calcium at week 48, alongside other important measures such as aortic valve area and cardiac structure and function. Kardigan expects to release topline data from this trial in the second half of 2026. This information could provide valuable insights into the effectiveness of ataciguat and its potential impact on treating aortic stenosis.
Background
Kardigan, Inc. is a company focused on pharmaceutical preparations, specifically in the area of developing innovative treatments for cardiovascular diseases. The company trades under the ticker symbol KARD on the Nasdaq exchange and is classified under the SIC code 2834, which pertains to pharmaceutical preparations. Kardigan is recognized as an emerging growth company, indicating its commitment to advancing healthcare solutions.
What the Filing Says
According to the recent SEC filing, "On November 6, 2026, Kardigan, Inc. issued a press release announcing that it had completed enrollment in its Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis." The filing also mentions that the primary endpoint will be assessed at week 48, with topline data expected later in 2026.
Impact
This development may have significant implications for patients suffering from aortic stenosis, as well as for healthcare providers and investors in the pharmaceutical sector. The results from the KATALYST-AV trial could influence treatment protocols and market dynamics within the pharmaceutical preparations industry.
What's Next
Kardigan will host an investor webcast from the American Heart Association Scientific Sessions on November 7, 2026, to discuss the trial and its implications. Further details regarding the outcomes of the trial will be provided as the data becomes available.
Read Next
Clark Kyle Sells 15,000 Shares of Beta Technologies Stock
Ronald R. Taylor resigns as director of ResMed Inc.
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares
StubHub Holdings' Mark Streams Sells 76,891 Shares
Francesca M. Edwardson Transfers 25,000 Shares to Trust




